Inhibition of bruton’s tyrosine kinase directly alleviates pathogenic CD4+ T cell response via PPAR-γ signaling in autoimmune uveitis Authors: Zhiqiang Xiao, Zhuang Li, Wenjie Zhu, Guanyu Chen, Xiaoshuang Luo, Zhiqing Mai, Minzhen Wang, Haixiang Huang, Zuoyi Li, Yuxun Shi, Yanyan Xie, Hao Wu, Xiaoqing Chen, Dan Liang Published: 2025 ABSTRACT BackgroundBruton’s tyrosine kinase (BTK), a key regulator of immune responses, has been extensively studied in B cells and innate immunocytes. Small-molecule BTK inhibitors (BTKi) have shown remarkable efficacy in multiple preclinical and clinical studies for autoimmune diseases via mediating the activation of B cells and innate immunocytes. Recent studies have demonstrated functional BTK expression in T cells, contributing to T cell activation and the pathogenesis of aplastic anemia. Whether BTK is involved in uveitis, the CD4+ T cell-mediated autoimmune disease, and whether it could be a therapeutic target remain unclear.MethodsWe assessed BTK expression and phosphorylation levels in CD4+ T cells from Autoimmune uveitis (AU) patients and experimental autoimmune uveitis (EAU) mice. By administering BTKi to EAU mice, we evaluated its effects on ocular and systemic inflammation levels through fundus photography, histopathology, qPCR, and flow cytometry. In vitro, we assessed its impact on the Th1/Th17/Treg differentiation, and the pathogenicity of CD4+ T cells. Transcriptomic sequencing and flow cytometry were employed to explore the potential mechanism by which BTK regulates CD4+ T cells.ResultsBTK expression and activation were upregulated in CD4+ T cells from AU patients and EAU mice. BTK inhibition suppressed the polarization of Th17 and Th1 cells, but not Treg differentiation. BTK inhibition upregulated the PPAR-γ signaling, alleviating oxidative stress and inflammatory responses in CD4+ T cells, thereby reducing ocular and systemic inflammation in EAU mice. Additionally, BTKi exhibited significant anti-inflammatory effects in CD4+ T cells from AU patients.ConclusionThis study demonstrates the critical role of BTK in CD4+ T cell-driven AU. BTK inhibition ameliorates oxidative stress and inflammatory responses via PPAR-γ involved signaling in CD4+ T cells and suppresses their differentiation to Th1/Th17 to restore immune homeostasis, thereby mitigating AU. These findings identify BTK as a potential therapeutic target and provide a theoretical foundation for the clinical application of BTKi in AU.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12974-025-03622-0. Background Bruton’s tyrosine kinase (BTK), a non-receptor tyrosine kinase of the Tec family, was traditionally thought to be expressed predominantly in B cells, where it plays a critical role in B cell receptor (BCR)-mediated proliferation, maturation and activation [1]. However, emerging evidence has revealed that BTK is also expressed in a variety of immune cells, including macrophages [2], neutrophils [3], and microglia [4], where it regulates their activation and phenotypic plasticity, thereby contributing to the pathogenesis of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. Notably, a recent study from Xu and Cao’s team demonstrated that BTK is also expressed in T lymphocytes and plays a role in the pathogenesis of autoimmune-mediated aplastic anemia [5]. This finding addressed the long-standing neglect regarding BTK expression and functions in T cells and provided a theoretical foundation for targeting BTK in T cell-mediated autoimmune diseases. Autoimmune uveitis (AU) is an inflammatory disease primarily mediated by CD4+ T cells. This irreversible ocular disorder severely impairs vision and causes blindness, with a blindness rate reaching 25–45% [6]. Globally, AU contributes to approximately 10% of all blindness cases, and this proportion increases to one-quarter of legal blindness cases in developing countries [7]. Experimental autoimmune uveitis (EAU), a well-established animal model for AU [8], has been used in almost all related pharmacological evaluations and mechanistic investigations. Previous studies from our group and others have demonstrated that pro-inflammatory CD4+ T cell subsets, including Th1/Th17, are the primary pathogenic drivers of AU, and suppressing the differentiation of CD4+ T cells into Th1/Th17 subsets, inhibiting their pathogenicity are critical therapeutic strategies [9–11]. However, the regulatory mechanisms governing the differentiation of these pathogenic cells in AU and whether BTK plays a role in this process warrants further exploration. Small-molecule BTK inhibitors (BTKi) represent the primary therapeutic strategy for targeted BTK modulation, owing to their distinct advantages such as high selectivity, superior tissue penetrability, favorable safety profiles and oral bioavailability [12–14]. Researchers have actively pursued the development of novel small-molecule BTK inhibitors, expanding their applications from initial use in B-cell malignancies to autoimmune diseases. Preclinical studies have demonstrated the efficacy of the BTKis including evobrutinib, tolebrutinib etc., in mouse model of autoimmune encephalomyelitis [4, 15–17], rheumatoid arthritis [18], systemic lupus erythematosus [19], and alcohol-associated liver disease [3]. Excitingly, recent Phase 3 randomized controlled trials (RCTs) have reported significant success of small-molecule BTK inhibitors in treating autoimmune conditions, including non-relapsing secondary progressive multiple sclerosis [20], immune thrombocytopenia [21], and chronic spontaneous urticaria [22]. Nevertheless, whether small-molecule BTKi can ameliorate AU remains unclear. In this study, we revealed the up-regulated expression and a high activation of BTK in CD4+ T cells from AU, and BTKi significantly alleviated EAU. Mechanistically, we illustrated that the BTK inhibition effectively suppressed CD4+ T cells’ differentiation towards Th1/Th17 and their pathogenicity, and restored immune homeostasis in AU. Our study revealed the role of BTK in pathogenic CD4+ T cells, and provided a theoretical foundation for the clinical application of BTKi in AU. Methods Mice In this study, female C57BL/6J mice aged 6 to 8 weeks were used. All mice were kept in a specific pathogen-free facility with cycles of 12 h of light and 12 h of darkness alternate and fed standard laboratory chow ad libitum. All mice were maintained at the Zhongshan Ophthalmic Center, Sun Yat-sen University. Subjects This study enrolled 15 patients with active Behçet’s disease uveitis (BDU) and 21 healthy subjects, all recruited from the Zhongshan Ophthalmic Center of Sun Yat-sen University. Participants were required to be aged between 18 and 60 years, with age and gender matched between two groups. The diagnosis of active BDU was based on the latest clinical criteria, including clinical manifestations, slit-lamp microscopy, and fluorescein angiography findings. Active BDU was defined as the presence of anterior chamber or vitreous cells in at least one eye, or retinal vascular leakage observed on fluorescein angiography. Healthy controls were required to have no history of autoimmune or inflammatory diseases. Participant information is provided in the Table.S1. Induction of EAU For active immunization-induced EAU [23], C57BL/6J mice were subcutaneously injected with 200 µg of hIRBP1 − 20 peptide (GL Biotech, Shanghai, China) emulsified in an equal volume of Complete Freund’s Adjuvant (CAT#F5506, Sigma-Aldrich, USA) containing 2.5 mg/ml Mycobacterium tuberculosis (CAT#231141, BD, USA) on day 0. Additionally, 200 ng of Pertussis toxin (CAT#180, List Biological Laboratories, USA) was administered intraperitoneally (i.p.) on days 0 and 2 post-immunization. Scoring of EAU Clinical scoring On day 14 after EAU inducing, the fundus images of mice by Micron IV Retina Imaging Microscope (PHONIX) were used for clinical scoring. The scores evaluation was on a scale of 0–4 based on the severity of inflammation [23]. In details, no lesion (score 0); few lesions or vasculitis (score 0.5); <5 lesions or mild vasculitis (score 1); >5 lesions or large vasculitis (score 2); large confluent lesions (score 3); retinal detachment (score 4). In addition, retinal angiography was supplied. Mice were injected intraperitoneally (i.p.) with 100ul 1% sodium fluorescein solution (CAT#46960-25G-F, Sigma-Aldrich, USA), and monitored for retinal vessels. Pathological scoring Mice were sacrificed on the day 14 after EAU inducing, and eyes were isolated and fixed with eyeball fixation solution overnight, and were then dehydrated, embedded and sectioned into 10 μm for H&E staining. The pathological scores were measured and evaluated under microscopy [23]. In details, no lesion (score 0); few inflammatory infiltrations (score 0.5); mild retinal folds (score 1); moderate retinal folds or retinal detachment (score 2); extensive retinal folds or large retinal detachment (score 3); diffuse retinal detachment (score 4). Drug Administration Starting from day 3 or day 8 post-EAU induction, mice in the BTKi-treated group received oral gavage of Evobrutinib (CAT#S8777, Selleck, USA), a highly selective BTKi, at a dose of 3 mg/kg, prepared in a vehicle solution containing 2% DMSO, 5% Tween-80, 20% PEG, and 73% water. The dosage of these solvent components is maintained within the mouse-tolerable range [24–26]. Control mice received an equivalent volume of the vehicle. Administration was performed once daily until day 13. For GW9662 (PPAR-γ antagonist) administration, GW9662 (1 mg/kg) or vehicle (1% DMSO + 2% Tween-80 + 10% PEG + 87% water) was administered intraperitoneally daily from day 3 to day 13 post-EAU induction. B Cells Depletion For depletion of B cells in mice, 250 µg of purified anti-mouse CD20 antibody (Cat#152115, BioLegend, USA) or isotype IgG (Cat#400671, BioLegend, USA) was administered via tail vein 3 days before EAU inducing. The efficiency of B cell depletion was subsequently assessed by flow cytometric analysis of peripheral blood collected from the tail vein two days post-antibody administration, as well as of lymph nodes harvested on the day of tissue collection. T Cell Apoptosis Assay CD4+ T cells isolated were seeded at 2 × 10^5 cells/well in 96-well plates and stimulated with anti-mouse CD3/CD28 microbeads (1 bead per 8 cells) in the presence of either the vehicle or various concentrations of BTKi. After 72 h, cells were collected and stained using the Annexin V-FITC Apoptosis Detection Kit (CAT#BMS500FI/100, Thermo Fisher Scientific, USA) according to the manufacturer’s instructions. Flow cytometry was performed to analyze Annexin V-FITC and propidium iodide (PI) staining. T Cell Differentiation Naïve CD4 +T cells (CD44 − CD62L+) were isolated from naïve mice using a naïve CD4 +T cell isolation kit (CAT#19765A, StemCell Technologies, CA), with purity confirmed by flow cytometry (> 95%). Cells were seeded at 2 × 10^5 cells/well in anti-CD3 (CAT#100239, BioLegend, USA) pre-coated 96-well plates and cultured under Th17, Th1, or Treg polarizing conditions in RPMI medium supplemented with 10% FBS and either the vehicle or varying concentrations of BTKi. Th17 polarization Cells were stimulated with 5 µg/mL anti-CD28 (CAT#102115, BioLegend, USA), 50 ng/mL IL-6 (CAT#406-ML-005/CF, R&D Systems, USA), 5ng/mL IL-23(CAT#589002, BioLegend, USA), 10 µg/mL anti-IFN-γ (CAT#505833, BioLegend, USA), 10 µg/mL anti-IL-4 (CAT#504121, BioLegend, USA), and 1 ng/mL TGF-β (CAT#BE0057, Bio X Cell, USA) for 5 days, with fresh medium replaced on day 3. Th1 polarization Cells were stimulated with 2 µg/mL anti-CD28 (CAT#102115, BioLegend, USA) and a Th1 differentiation kit (CAT#10953, StemCell Technologies, CA), for 5 days, with fresh medium replaced on day 3. Treg polarization Cells were stimulated with 2 µg/mL anti-CD28 (CAT#102115, BioLegend, USA), 10 ng/mL TGF-β (CAT#BE0057, Bio X Cell, USA), and 10 ng/mL IL-2 (CAT#575402, BioLegend, USA) for 4 days. After differentiation, cells were harvested and analyzed by flow cytometry to determine the proportions of Th17 (CD4+ IL-17A+), Th1 (CD4+ IFN-γ+), and Treg (CD4+ CD25+ FOXP3+) cells. T Cell IRBP response Assay On day 14 post-immunization, lymph node cells were isolated from actively immunized EAU mice and seeded at 2 × 10^5 cells/well in 96-well plates. Cells were stimulated with hIRBP1 − 20 (10 µg/mL) and cultured in the presence of either the vehicle (0.05% DMSO) or varying concentrations of BTKi for 72 h. Then, cells were harvested and analyzed by flow cytometry to determine the proportions of IL-17A+, IFN-γ+, and GMCSF+ CD4+ T cells respectively. For the BTKi-GW9662 co-treatment assay, the BTKi group received 1 µM Evobrutinib (0.05% DMSO), while the BTKi + GW9662 group received both 1 µM Evobrutinib and 1 µM GW9662 (final 0.05% DMSO). Both non-IRBP and vehicle control groups were administered an equivalent concentration of DMSO. Generation of MHC Class II (I-Ab) IRBP4 − 15 Tetramers (Tet) MHC class II (I-Ab) tetramers presenting the immunodominant peptide IRBP4 − 15 (HLFQPSLVLDMA) were engineered to detect TCRα/β specific for the IRBP1 − 20/MHC-II complex. The extracellular domains of I-Ab α- and β-chains were individually cloned into a pCDH-MSCV-MCS-EF1a-GFP-PURO lentiviral backbone. The IRBP4 − 15 peptide was fused to the β-chain N-terminus via a 13-amino acid flexible linker [27], while complementary leucine zipper motifs with a 6×His tag (β-chain) and AviTag (α-chain) were incorporated for heterodimer formation and purification [28]. After co-expression in murine JAWSII dendritic cells, heterodimers were isolated from lysates using anti-His magnetic beads (Beyotime), biotinylated with BirA enzyme (Beyotime) via the AviTag, eluted with 6×His peptide, and assembled into tetramers using PE-Cy7-conjugated streptavidin (eBioscience). These tetramers were subsequently used in flow cytometric assays to identify IRBP-specific (Tet+) CD4+ T cells. Adoptive transfer experiment IRBP-specific CD4+ T cells were transferred into naïve recipient mice to directly induce uveitis [23]. Briefly, lymph node cells were isolated from actively immunized EAU donor mice and stimulated with hIRBP1 − 20 (10 µg/ml) for 72 h. Subsequently, IRBP-specific CD4+ T cells were sorted by flow cytometry and intravenously injected into naïve recipient mice at a dose of 2 × 10^6 cells per mouse. Flow Cytometry Tissues were homogenized into single-cell suspensions in RPMI medium supplemented with 2% FBS and filtered through a 70 μm cell strainer. Cells were washed with PBS and stained using the Zombie NIR™ Fixable Viability Kit (CAT#423106, BioLegend, USA) for 10 min. After washing, surface staining was performed by incubating cells with surface antibodies at room temperature for 15 min. For intracellular cytokine staining, cells were stimulated with Cell Stimulation Cocktail (Invitrogen, USA) in 10% FBS-supplemented medium for 4–6 h. Cells were then collected, stained for viability and surface markers as described above, and fixed/permeabilized using the FOXP3 Fix/Prem Buffer (CAT#421401, Biolegend, USA) and Permeabilization Buffer (CAT#00–8333-56, Invitrogen, USA). Intracellular antibodies were added, and cells were stained overnight at 4 °C. For phosphoprotein staining, cells were fixed with BD Phosflow FixBuffer I (CAT#557870, BD Bioscience, USA) at 37 °C for 10–15 min, followed by extensive PBS washing. Membrane permeabilization was then performed using Phosflow PermBuffer II (CAT#558050, BD Bioscience, USA) on ice for 30 min. After washing with PBS, antibodies were applied for overnight staining at 4 °C. The detail of the antibody used in this study was shown in Table.S2. Samples were analyzed on a Cytek flow cytometer (Cytek, USA), and data were processed using FlowJo software (v10.4). PBMC Stimulation Assay Peripheral blood mononuclear cells (PBMCs) were isolated from participant blood samples using Ficoll (CAT#17144003, Cytiva, Sweeden) density gradient centrifugation. PBMCs were seeded at 2 × 10^5 cells/well in 96-well plates and stimulated with anti-human CD3/CD28 beads (CAT#11131D, Thermo Fisher Scientific, USA) (1 bead per 4 cells) in the presence of either vehicle or varying concentrations of BTKi. After 72 h of culture, cells were harvested for flow cytometric analysis. Quantitative real-time PCR (qPCR) Retinal tissue were dissected from each group and homogenized for RNA extraction. Total RNA was isolated with the Tissue RNA Purification Kit Plus (CAT#RN002plus, ESScience, China), and its concentration/purity was determined by NanoDrop spectrophotometer (Thermo Fisher Scientific, USA). Subsequently, cDNA synthesis was performed with PrimeScript RT Master Mix (CAT#RR360A, TaKaRa Bio Inc., Japan) following the manufacturer’s protocol. qPCR assays were conducted using SYBR Premix Ex Taq II (CAT#RR820A, TaKaRa Bio Inc., Japan). mRNA levels of Ifng, Il17a, Il6, and Tnf (primer sequences synthesized by Sangon Biotech, Shanghai, China) were normalized to the endogenous control gapdh and calculated via the 2–ΔΔCt method. Bulk RNA Sequencing (Bulk RNA-seq) On day 14 post-immunization, lymph node cells were isolated from four EAU mice and stimulated with hIRBP1− 20. Cells were cultured in RPMI medium supplemented with 10% FBS and either the vehicle (0.1% DMSO) or 1µM BTKi for 72 h. Then cells were stained using the Zombie NIR™ Fixable Viability Kit and anti-CD4 antibody. Viable CD4+ T cells (zombie− CD4+) were sorted using a flow cytometer (BD, USA), with a purity exceeding 99%. Total RNA was extracted from CD4+ T cells using TRIzol reagent (Invitrogen, USA) following the manufacturer’s guidelines. RNA purity and concentration were measured using a NanoDrop 2000 spectrophotometer (Thermo Scientific, USA), while RNA integrity was verified with an Agilent 2100 Bioanalyzer (Agilent Technologies, USA). Sequencing libraries were prepared using the VAHTS Universal V6 RNA-seq Library Prep Kit as per the manufacturer’s instructions. The libraries were sequenced on the Illumina Novaseq 6000 platform, generating 150 bp paired-end reads. Raw fastq files were preprocessed with fastp [29] to filter out low-quality reads. Clean reads were aligned to the reference genome using HISAT2 [30]. Gene expression levels were quantified as FPKM [31], and read counts per gene were obtained using HTSeq-count [32]. Principal component analysis (PCA) was conducted in R (v 3.2.0) to assess sample reproducibility. Differential expression analysis was performed using DESeq2 [33], with significantly differentially expressed genes (DEGs) defined as those with a Q value < 0.05 and a fold change >2 or < 0.5. Hierarchical clustering of DEGs was carried out in R (v 3.2.0) to visualize gene expression patterns across groups and samples. Functional enrichment analysis of DEGs was conducted based on the hypergeometric distribution, covering Gene Ontology (GO), KEGG pathways, and WikiPathways. Significant terms were identified using R (v 3.2.0), and results were visualized as column diagrams and bubble diagrams. Statistical Analysis Comparisons between two groups were performed using Student’s unpaired two-tailed t-test. For comparisons involving more than two groups, one-way ANOVA followed by post-hoc pairwise comparisons with correction for multiple testing was applied. Data are presented as mean ± standard deviation (SD). *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001, and nsp refers to no significancy. For animal experiment data with substantial intra-group standard deviation, we have reported 95% confidence intervals for all comparisons (Table. S3). All statistical analyses were conducted using GraphPad Prism 9. Results BTK is upregulated and activated in CD4+ T cells from EAU mice Given the critical role of the balance between Th17 (the principal pro-inflammatory effector subset of CD4+ T lymphocytes) and Treg (the dominant immunosuppressive regulatory counterpart) in AU, we first conducted in vitro analyses comparing BTK expression and activation during CD4+ T cell polarization. Strikingly, Th17-polarized cells exhibited a significantly higher BTK expression and increased phospho-BTK (Tyr223) levels versus Treg-polarized and undifferentiated Th0 cells, as analyzed by flow cytometry (Fig. 1A, B).Fig. 1Upregulation and Activation of BTK in CD4+ T Cells from EAU Mice. A-B Flow cytometry histograms and bar graphs show that the geometric mean fluorescence intensity (gMFI) of BTK and phospho-BTK (p-BTK) in Th17-polarized (RORγt+) and Treg-polarized (Foxp3+) CD4+ T cells, as well as undifferentiated Th0 (RORγt- Foxp3- CD4+). C-D Flow cytometry histograms and bar graphs show that the gMFI of BTK and p-BTK in CD4+ T cells from lymph nodes of EAU mice is significantly higher than that of blank control mice. E-F Flow cytometry was further used to analyze BTK and p-BTK expression levels in Th17 (CD4+ RORγt+) and Treg (CD4+ Foxp3+) cells from lymph nodes of EAU and blank control mice. Data are presented as mean ± SD, n=6-10. Statistical analysis was performed using t-tests and ANOVA. *p<0.05, **p<0.01, ***p<0.005, ****p<0.001,nsp≥0.05 Upregulation and Activation of BTK in CD4+ T Cells from EAU Mice. A-B Flow cytometry histograms and bar graphs show that the geometric mean fluorescence intensity (gMFI) of BTK and phospho-BTK (p-BTK) in Th17-polarized (RORγt+) and Treg-polarized (Foxp3+) CD4+ T cells, as well as undifferentiated Th0 (RORγt- Foxp3- CD4+). C-D Flow cytometry histograms and bar graphs show that the gMFI of BTK and p-BTK in CD4+ T cells from lymph nodes of EAU mice is significantly higher than that of blank control mice. E-F Flow cytometry was further used to analyze BTK and p-BTK expression levels in Th17 (CD4+ RORγt+) and Treg (CD4+ Foxp3+) cells from lymph nodes of EAU and blank control mice. Data are presented as mean ± SD, n=6-10. Statistical analysis was performed using t-tests and ANOVA. *p<0.05, **p<0.01, ***p<0.005, ****p<0.001,nsp≥0.05 To clarity the in vivo relevance, we further analyzed BTK expression and activation in CD4+ T cells of EAU mice and blank control mice. Our results revealed that both BTK expression and its phosphorylation levels were significantly elevated in CD4+ T cells from EAU mice compared to blank controls (Fig. 1C, D). In addition, they were much higher in Th17 cells from EAU compared with those from blank control mice. However, in Treg cells, BTK phosphorylation showed no significant differences between EAU mice and blank control, although a modest upward trend was observed in the EAU group. (Fig. 1E, F). We further evaluated the preference of BTK expression and activation between Th17 and Treg in vivo. In accordance with results in vitro, in EAU mice, a significantly higher level of BTK expression and phosphorylation were observed in Th17 cells compared with Treg cells (Fig. 1E). These findings uncovered heterogeneous BTK expression and activation states across CD4+ T cell subsets, implicating a potential role of BTK in driving EAU via pathogenic CD4+ T cell lineages. BTK Inhibition alleviates ocular inflammation in EAU mice To determine whether BTK inhibition could alleviate EAU, we used evobrutinib, a highly selective BTK inhibitor (BTKi), as BTK inhibition treatment in our study. C57BL/6j mice underwent EAU induction on day 0 and were administered BTKi (3 mg/kg) [16] or vehicle daily via oral gavage from day 3 (Fig. 2A). On day 14, we examined the fundus of the mice. Vehicle-treated EAU mice exhibited significant retinal edema, vascular dilation, tortuosity, leakage, and perivascular sheathing, whereas BTKi-treated EAU mice showed no apparent lesions, with a significant reduction in the clinical scores (Fig. 2B, C). The fluorescein angiography demonstrated substantial mitigation of retinal vascular lesions by BTKi (Fig. 2B). In addition, pathology showed that vehicle-treated EAU mice had pronounced retinal folds, structural disorganization, and inflammatory cell infiltration with significantly higher pathological scores than BTKi-treated mice (Fig. 2B, D). Meaningfully, EAU mice receiving BTKi from day 8 post-immunization when early fundus signs of EAU had been observed, also exhibited alleviated fundus lesions (Fig. S2A-D).Fig. 2BTKi Alleviates Ocular Inflammation in EAU Mice. A Schematic of the experimental design. B Representative fundus and retinal H&E staining of blank control mice, vehicle-treated EAU mice and BTKi-treated EAU mice. C-D Bar graphs demonstrate that BTKi significantly reduced clinical and pathological scores in EAU mice. E qPCR analysis of retinal tissue. Bar graphs show that BTKi significantly decreased mRNA levels of inflammatory cytokines, including Il17a, Ifng, Tnf, and Il6, in EAU mice. F Flow cytometry analysis of intraocular inflammatory cell infiltration in BTKi- and vehicle-treated EAU mice. Flow plots and bar graphs reveal extensive infiltration of total leukocytes (CD45+) and CD4+ T cells in vehicle-treated EAU mice, along with a high proportion of pro-inflammatory T cells, including Th17 (CD4+ IL-17A+), Th1 (CD4+ IFN-γ+), GMCSF+ CD4+ T cells, and TNF-α+ CD4+ T cells. In contrast, BTKi-treated EAU mice showed significantly reduced infiltration of these inflammatory cells. Data are presented as mean ± SD, n=8-10. Statistical analysis was performed using t-tests. *p<0.05,**p<0.01,***p<0.005,****p<0.001,nsp≥0.05 BTKi Alleviates Ocular Inflammation in EAU Mice. A Schematic of the experimental design. B Representative fundus and retinal H&E staining of blank control mice, vehicle-treated EAU mice and BTKi-treated EAU mice. C-D Bar graphs demonstrate that BTKi significantly reduced clinical and pathological scores in EAU mice. E qPCR analysis of retinal tissue. Bar graphs show that BTKi significantly decreased mRNA levels of inflammatory cytokines, including Il17a, Ifng, Tnf, and Il6, in EAU mice. F Flow cytometry analysis of intraocular inflammatory cell infiltration in BTKi- and vehicle-treated EAU mice. Flow plots and bar graphs reveal extensive infiltration of total leukocytes (CD45+) and CD4+ T cells in vehicle-treated EAU mice, along with a high proportion of pro-inflammatory T cells, including Th17 (CD4+ IL-17A+), Th1 (CD4+ IFN-γ+), GMCSF+ CD4+ T cells, and TNF-α+ CD4+ T cells. In contrast, BTKi-treated EAU mice showed significantly reduced infiltration of these inflammatory cells. Data are presented as mean ± SD, n=8-10. Statistical analysis was performed using t-tests. *p<0.05,**p<0.01,***p<0.005,****p<0.001,nsp≥0.05 We further collected retinal tissue for qPCR analysis, and the results demonstrated significantly reduced mRNA levels of inflammatory cytokines such as Il17a, Ifng, Tnf, and Il6 in the BTKi group (Fig. 2E). We also collected retinal tissue and intraocular fluids for flow cytometry, and found that BTKi treatment markedly reduced the infiltration of CD45 + immune cells, particularly CD4+ T cells, including IL-17 A+, IFN-γ+, TNF-α+, and GMCSF + inflammatory subsets (Fig. 2F). In summary, BTKi effectively suppressed ocular inflammation and ameliorated EAU. BTK Inhibition alleviates CD4+ T Cell-Mediated systemic inflammation in EAU On day 14, we sacrificed the EAU mice and assessed the CD4+ T cell-mediated systemic immune inflammation by flow cytometry. First of all, we confirmed BTKi inhibited the BTK expression and phosphorylation in CD4+ T cells of EAU mice (Fig. 3A, B). Following, we examined the proportions of Th17, Th1, and GMCSF+ CD4+ T cells, which are the pathogenic subsets driving inflammation in EAU. As anticipated, BTK inhibition significantly reduced the proportions of these T cell subsets both in the lymph nodes and the spleen (Fig. 3C, E). Administration of BTKi from day 8 post-immunization of EAU mice yielded consistent results (Fig.S2E-F). However, no statistically significant difference was observed in the proportion of Treg cells between two groups (Fig. 3D, F).Fig. 3BTKi Alleviates CD4+ T Cell-Mediated Inflammation. A-B Flow cytometry histograms and bar graphs show that the gMFI of BTK and p-BTK in CD4+ T cells in draining lymph nodes from BTKi-treated EAU mice were significantly lower than that from vehicle-treated EAU mice. C-F The proportions of CD4+ T cell subsets, including Th17, Th1, GMCSF+ CD4 T cells, and Treg (CD4+ CD25+ FOXP3+) in lymph nodes and spleens from vehicle- and BTKi-treated EAU mice. G, H The CD69 expression in CD4+ T cells from vehicle- and BTKi-treated EAU mice. I-N The proportion changes of the effector (CD44+ CD62L-) and naïve (CD44- CD62L+) CD4+ T cells in vehicle- and BTKi-treated EAU mice. Data are presented as mean ± SD, n=7. Statistical analysis was performed using t-tests. *p<0.05,**p<0.01,***p<0.005,****p<0.001,nsp≥0.05 BTKi Alleviates CD4+ T Cell-Mediated Inflammation. A-B Flow cytometry histograms and bar graphs show that the gMFI of BTK and p-BTK in CD4+ T cells in draining lymph nodes from BTKi-treated EAU mice were significantly lower than that from vehicle-treated EAU mice. C-F The proportions of CD4+ T cell subsets, including Th17, Th1, GMCSF+ CD4 T cells, and Treg (CD4+ CD25+ FOXP3+) in lymph nodes and spleens from vehicle- and BTKi-treated EAU mice. G, H The CD69 expression in CD4+ T cells from vehicle- and BTKi-treated EAU mice. I-N The proportion changes of the effector (CD44+ CD62L-) and naïve (CD44- CD62L+) CD4+ T cells in vehicle- and BTKi-treated EAU mice. Data are presented as mean ± SD, n=7. Statistical analysis was performed using t-tests. *p<0.05,**p<0.01,***p<0.005,****p<0.001,nsp≥0.05 To exclude the involvement of B cells, we administered a purified anti-mouse CD20 antibody to deplete B cells prior to EAU induction (Fig.S3A). Successful B cell depletion was confirmed by flow cytometry analysis (Fig.S3B, C). We observed that EAU could be successfully induced in B cell-depleted mice (Fig.S3D). Consistently, the BTKi-treated mice exhibited a lower clinical and pathological score compared with the vehicle group (Fig.S3D, E). Moreover, flow cytometric analysis also demonstrated that BTK inhibition reduced the proportions of Th1, Th17, and GMCSF+ CD4+ T cells in lymph nodes and spleen of B cell-depleted EAU mice (Fig.S3F-G). These indicate that BTK inhibition ameliorates the CD4 + T cell-mediated immune inflammation, which occurs independently of B cells. To further assess the activation of CD4+ T cells, we evaluated the expression of CD69, an activation marker of CD4+ T cells, and the results showed that the proportion of CD69+ CD4+ T cells was markedly reduced in BTKi-treated EAU mice (Fig. 3G, H), indicating suppressed T cell activation. Considering that in EAU mice, naïve CD4+ T cells (CD44- CD62L+) undergo activation and turned into effector populations (CD44+ CD62L-) upon IRBP stimulation, we further quantified the proportions of these two subsets. The results showed that BTKi significantly decreased the proportions of effector CD4+ T cells while increasing the proportion of naïve CD4 + T cells in the draining lymph nodes (Fig. 3I-K), and similar results were observed in the spleen (Fig. 3L-N). Our findings indicate that BTK inhibition alleviates systemic immune inflammation in EAU mice by modulating the activation and composition of pathogenic CD4+ T cell subsets. BTK Inhibition impairs Th17/Th1 polarization in vitro To further investigate how BTK inhibition modulates CD4+ T cell to suppress immune inflammation, we evaluated its effects on CD4 + T cell polarization. First, we treated CD4+ T cell with three concentrations (100 nM, 1 µM, and 10 µM) of BTKi, and found that BTKi concentrations did not significantly affect lymphocytes viability (Fig. S4A, B) and apoptosis (Fig. S4C-E) in vitro. Then, naïve CD4+ T cells were treated with vehicle or BTKi and cultured in Th17, Th1, or Treg polarizing media for 4 to 5 days. Consistent with our in vivo results, BTK inhibition significantly suppressed the polarization of Th17 (Fig. 4A, B) and Th1 (Fig. 4C, D) cells but had no notable effect on Treg differentiation (Fig. 4E, F). In summary, BTKi specifically inhibited the differentiation of CD4+ T cells into pro-inflammatory Th17 and Th1 subsets, but not affecting Treg differentiation. These results revealed the key role of BTK on Th17/Th1 polarization.Fig. 4BTKi suppresses the differentiation of Th1/Th17 but not Treg. A-F Representative flow cytometry plots and bar graphs show that BTKi significantly suppressed Th17 A,B and Th1 C,D polarization, but not Treg E,F. Data are presented as mean ± SD. Statistical analysis was performed using ANOVA analysis. *p<0.05,**p<0.01,***p<0.005,****p<0.001,nsp≥0.05 BTKi suppresses the differentiation of Th1/Th17 but not Treg. A-F Representative flow cytometry plots and bar graphs show that BTKi significantly suppressed Th17 A,B and Th1 C,D polarization, but not Treg E,F. Data are presented as mean ± SD. Statistical analysis was performed using ANOVA analysis. *p<0.05,**p<0.01,***p<0.005,****p<0.001,nsp≥0.05 BTK Inhibition suppresses the IRBP-specific response and pathogenicity of CD4 + T cells IRBP-specific T cells are central drivers in the pathogenesis of EAU. Our previous studies have shown that IRBP can activate IRBP-specific T lymphocytes in vitro, promoting their differentiation into Th1 and Th17 subsets and triggering the secretion of pro-inflammatory cytokines [11, 34]. To determine whether BTK inhibition suppresses IRBP responses in CD4+ T cells, we isolated cells of lymph nodes from EAU mice and re-stimulated them with hIRBP1 − 20 in the presence of vehicle or different concentrations of BTKi for 3 days. Flow cytometry analysis revealed that BTKi significantly reduced the proportions of Th1, Th17, and GMCSF+ CD4+ T cells (Fig. 5A-D), indicating that BTK inhibition effectively suppressed IRBP responses in CD4+ T cells in vitro.Fig. 5BTKi Suppresses the Inflammatory Response and Pathogenicity of IRBP-specific CD4+ T cells. A-D Representative flow cytometry plots and bar graphs show that BTKi significantly reduced the proportions of IRBP-induced Th1, Th17, and GMCSF+ CD4+ T cells in vitro. E Schematic of the experimental procedure. Lymph node cells from EAU mice were isolated and cultured with hIRBP1-20 (10 μg/ml) for 72 hours in the presence of BTKi (1 μM) or vehicle. IRBP-specific (Tet+) CD4+ T cells were sorted and adoptively transferred into naïve recipient mice. F Clinical and pathological scores in recipient mice receiving BTKi-treated IRBP-specific CD4+ T cells were significantly lower than those in the vehicle control group. n=10. G-L Representative flow cytometry plots and bar graphs illustrate that mice receiving BTKi-treated IRBP-specific CD4+ T cells showed significantly reduced infiltration of inflammatory cells. Data are presented as mean ± SD, n=6-10. Statistical analysis was performed using ANOVA analysis and t-tests. *p<0.05,**p<0.01,***p<0.005,****p<0.001,nsp≥0.05 BTKi Suppresses the Inflammatory Response and Pathogenicity of IRBP-specific CD4+ T cells. A-D Representative flow cytometry plots and bar graphs show that BTKi significantly reduced the proportions of IRBP-induced Th1, Th17, and GMCSF+ CD4+ T cells in vitro. E Schematic of the experimental procedure. Lymph node cells from EAU mice were isolated and cultured with hIRBP1-20 (10 μg/ml) for 72 hours in the presence of BTKi (1 μM) or vehicle. IRBP-specific (Tet+) CD4+ T cells were sorted and adoptively transferred into naïve recipient mice. F Clinical and pathological scores in recipient mice receiving BTKi-treated IRBP-specific CD4+ T cells were significantly lower than those in the vehicle control group. n=10. G-L Representative flow cytometry plots and bar graphs illustrate that mice receiving BTKi-treated IRBP-specific CD4+ T cells showed significantly reduced infiltration of inflammatory cells. Data are presented as mean ± SD, n=6-10. Statistical analysis was performed using ANOVA analysis and t-tests. *p<0.05,**p<0.01,***p<0.005,****p<0.001,nsp≥0.05 To assess the pathogenic potential of BTKi-treated IBRP-specific CD4+ T cells in vivo, we developed fluorescent MHC class II–IRBP peptide tetramers (Tet) for precise detection and isolation of IRBP-specific CD4+ T cells. After cultured with either vehicle or BTKi under IRBP stimulation, IRBP-specific CD4+ T cells were isolated and adoptively transferred into naïve mice via tail vein injection (Fig. 5E). 14 days post-transfer, we found that mice receiving BTKi-treated IRBP-specific CD4+ T cells exhibited significantly lower clinical and pathological scores compared to the vehicle-treated group (Fig. 5F). Additionally, flow cytometry analysis of intraocular immune cell infiltration revealed a marked reduction in inflammatory cells, including Th17, Th1, and GMCSF+ CD4+ T cells, in mice receiving BTKi-treated cells (Fig. 5G-L). In summary, our findings demonstrated that BTK inhibition suppressed IRBP-specific responses in CD4+ T cells and effectively reduced their pathogenic potential. BTK Inhibition ameliorates oxidative stress and immune inflammation in CD4+ T cells with PPAR-γ involvement To further elucidate the potential mechanisms, CD4+ T cells were treated with either vehicle or BTKi for transcriptomic sequencing. Transcriptomic analysis revealed that BTKi markedly altered the transcriptional profile and the functional partition of CD4+ T cells (Fig.S5A-D). Furthermore, WikiPathways (Fig. 6A) and KEGG (Fig. 6C) enrichment analyses indicated significant downregulation of cytokine- and inflammation-related pathways, including the NF-κB signaling pathway, IL-17A signaling pathway, as well as oxidative stress and damage-related pathways.Fig. 6BTKi Ameliorates Oxidative Stress and Immune Inflammation in CD4+T Cells with PPAR-γ Involvement. A-B Bubble plots show the results of Wikipathways enrichment analysis of differentially expressed genes (DEGs). C-D Bubble plots show the results of KEGG enrichment analysis of DEGs. E Representative flow cytometry histograms and bar graphs show the gMFI of ROS in CD4+ T cells treated with BTKi or vehicle in vitro. F Representative flow cytometry histograms and bar graphs show the gMFI of ROS in CD4+ T cells from lymph nodes of BTKi- and vehicle-treated EAU mice. G Representative flow cytometry histograms and bar graphs show the gMFI of p-p65 in CD4+ T cells treated with BTKi or vehicle in vitro. H Representative flow cytometry histograms and bar graphs show the gMFI of p-p65 in CD4+ T cells from draining lymph nodes of BTKi-treated and vehicle-treated EAU mice. I PPI network analysis, based on differentially expressed genes enriched in oxidative stress, oxidative damage, and immune inflammation-related pathways, reveals significant interactions among the NF-κB signaling pathway, oxidative stress and damage pathways, and PPAR signaling pathway. J Representative flow cytometry histograms and bar graphs show the gMFI of PPAR-γ in CD4+ T cells from draining lymph nodes of BTKi-treated EAU mice and vehicle-treated EAU mice. K Representative flow cytometry histograms and bar graphs show the gMFI of PPAR-γ in CD4+ T cells treated with BTKi or vehicle in vitro. L Representative flow cytometry plots and bar graphs show that the PPAR-γ antagonist GW9662 prevented the inhibitory effects of BTKi on the proportions of Th17, Th1, and GMCSF+ CD4+ T cells. n=8. M Representative fundus images and bar graphs demonstrate that the PPAR-γ antagonist GW9662 reduced the therapeutic effects of BTKi in EAU mice clinically and pathologically. n=10. Data are presented as mean ± SD. n = 6-10. Statistical analysis was performed using ANOVA analysis. *p<0.05,**p<0.01,***p<0.005,****p<0.001,nsp≥0.05 BTKi Ameliorates Oxidative Stress and Immune Inflammation in CD4+T Cells with PPAR-γ Involvement. A-B Bubble plots show the results of Wikipathways enrichment analysis of differentially expressed genes (DEGs). C-D Bubble plots show the results of KEGG enrichment analysis of DEGs. E Representative flow cytometry histograms and bar graphs show the gMFI of ROS in CD4+ T cells treated with BTKi or vehicle in vitro. F Representative flow cytometry histograms and bar graphs show the gMFI of ROS in CD4+ T cells from lymph nodes of BTKi- and vehicle-treated EAU mice. G Representative flow cytometry histograms and bar graphs show the gMFI of p-p65 in CD4+ T cells treated with BTKi or vehicle in vitro. H Representative flow cytometry histograms and bar graphs show the gMFI of p-p65 in CD4+ T cells from draining lymph nodes of BTKi-treated and vehicle-treated EAU mice. I PPI network analysis, based on differentially expressed genes enriched in oxidative stress, oxidative damage, and immune inflammation-related pathways, reveals significant interactions among the NF-κB signaling pathway, oxidative stress and damage pathways, and PPAR signaling pathway. J Representative flow cytometry histograms and bar graphs show the gMFI of PPAR-γ in CD4+ T cells from draining lymph nodes of BTKi-treated EAU mice and vehicle-treated EAU mice. K Representative flow cytometry histograms and bar graphs show the gMFI of PPAR-γ in CD4+ T cells treated with BTKi or vehicle in vitro. L Representative flow cytometry plots and bar graphs show that the PPAR-γ antagonist GW9662 prevented the inhibitory effects of BTKi on the proportions of Th17, Th1, and GMCSF+ CD4+ T cells. n=8. M Representative fundus images and bar graphs demonstrate that the PPAR-γ antagonist GW9662 reduced the therapeutic effects of BTKi in EAU mice clinically and pathologically. n=10. Data are presented as mean ± SD. n = 6-10. Statistical analysis was performed using ANOVA analysis. *p<0.05,**p<0.01,***p<0.005,****p<0.001,nsp≥0.05 As known, NF-κB is a critical transcription factor that promotes the transcription of various inflammatory genes in immune cells. Among its subunits, p65 plays a pivotal role in regulating NF-κB transcriptional activity through phosphorylation, thereby triggering immune inflammation [35]. In addition, excessive oxidative stress also reflects cellular inflammatory phenotypes. Our previous work showed that reactive oxygen species (ROS) drove CD4+ T cell inflammation and exacerbated AU [11]. Here, our data showed that BTK inhibition significantly downregulated ROS and p-p65 levels, as well as TNF-α (the NF-κB downstream inflammatory cytokine) in CD4 + T cells under IRBP stimulation in vitro (Fig. 6E, G, Fig.S6B). Similarly, in vivo experiments demonstrated that BTKi decreased ROS levels of ocular tissue and CD4 + T cells (Fig.S6A, Fig. 6F), and decreased p-p65 levels of CD4 + T cells (Fig. 6H) were also observed in EAU mice. These results indicated that BTK inhibition alleviates oxidative stress and inflammation by reducing ROS levels and NF-κB activation in CD4 + T cells. Peroxisome proliferator-activated receptor-γ (PPAR-γ), a member of PPARs family, is widely expressed in various immune cells and plays a crucial role in modulating oxidant stress [36] and inflammation [37, 38]. And in our sequencing data, the significant upregulation of the PPAR signaling was observed (Fig. 6B, D). Protein-protein interaction (PPI) network analysis also revealed significant interactions among the PPARs signaling pathway, oxidative stress and damage pathways, and the NF-κB signaling pathway (Fig. 6I). Further, flow cytometry demonstrated that BTKi significantly upregulated PPAR-γ expression in CD4 + T cells of EAU mice (Fig. 6J) or under IRBP stimulation (Fig. 6K). We next used the PPAR-γ specific antagonist 2-Chloro-5-nitro-N-phenylbenzamide (GW9662), which could covalently bind to the PPAR-γ and block the PPAR-γ signaling [39, 40]. We found that GW9662 prevented the immunomodulatory effects on CD4 + T cells of BTKi in vitro (Fig. 6L). In vivo experiments also indicated that co-administration of GW9662 with BTKi reduced the therapeutic effects of BTK inhibition in EAU (Fig. 6M). Collectively, BTK inhibition ameliorates oxidative stress and immune inflammation in CD4+ T cells of EAU, and the PPAR-γ signaling is involved in this procedure. BTK inhibition alleviates CD4+ T cell-inflammation in patients with Behçet’s disease uveitis in vitro To further assess the clinical translatability of our findings from animal models, we collected peripheral blood mononuclear cells (PBMCs) from 15 patients with active Behçet’s disease uveitis (BDU), a common form of autoimmune uveitis [6], and 21 healthy controls. Flow cytometry analysis revealed that BTK expression and activation were significantly increased in CD4+ T cells from active BDU patients (Fig. 7A-C). Notably, BTK expression and activation were higher in Th17 cells than non-Th1/Th17 CD4+ T cells (without IL-17 A or IFN-γ secretion) (Fig. 7D-F).Fig. 7BTK Aberrant Activation in CD4+ T Cells of BDU Patients and Immunomodulation by BTKi in Vitro. A-C Flow cytometry histograms and violin plots show the gMFI of BTK and p-BTK in CD4+ T cells from patients with active BDU and healthy controls. n=15 and 21. D-F Flow cytometry histograms and violin plots demonstrate the gMFI of BTK and p-BTK in Th1, Th17 and non-Th1/Th17 CD4+ T cell subsets. n=15 and 21. G-K Representative flow cytometry plots and violin plots show that BTKi significantly reduced the expression of pro-inflammatory cytokines IL-17A, IFN-γ and GMCSF in CD4+ T cells from active BDU patients, but has no significant effect on Treg. Statistical analysis was performed using ANOVA and t-tests. *p<0.05,**p<0.01,***p<0.005,****p<0.001,nsp≥0.05 BTK Aberrant Activation in CD4+ T Cells of BDU Patients and Immunomodulation by BTKi in Vitro. A-C Flow cytometry histograms and violin plots show the gMFI of BTK and p-BTK in CD4+ T cells from patients with active BDU and healthy controls. n=15 and 21. D-F Flow cytometry histograms and violin plots demonstrate the gMFI of BTK and p-BTK in Th1, Th17 and non-Th1/Th17 CD4+ T cell subsets. n=15 and 21. G-K Representative flow cytometry plots and violin plots show that BTKi significantly reduced the expression of pro-inflammatory cytokines IL-17A, IFN-γ and GMCSF in CD4+ T cells from active BDU patients, but has no significant effect on Treg. Statistical analysis was performed using ANOVA and t-tests. *p<0.05,**p<0.01,***p<0.005,****p<0.001,nsp≥0.05 Next, we stimulated PBMCs from BDU patients with anti-CD3/CD28 for 3 days in the presence of different concentrations of BTKi or vehicle. Consistent with our findings in mouse model, BTK inhibition significantly reduced the secretion of inflammatory cytokines of CD4+ T cells, including IL-17 A, IFN-γ and GMCSF, without impact on the proportion of Treg cells (Fig. 7G). These results indicated that BTK expression and activation were upregulated in CD4+ T cells from BDU patients, and in vitro treatment with BTKi effectively suppressed Th1/Th17 cell differentiation and inflammatory cytokine secretion in CD4+ T cells from BDU patients. Discussion Growing evidence suggests that BTK plays a critical role in autoimmune diseases, and researchers are continuously developing novel small-molecule BTK inhibitors for their treatment. In this study, we elucidated the role of BTK in CD4+ T cell-mediated AU and demonstrated that inhibiting BTK effectively alleviates inflammation in both the mouse model and CD4+ T cells from AU patients. Mechanistically, BTK inhibition suppresses the differentiation of CD4+ T cells into pathogenic Th17/Th1 subsets and ameliorates oxidative stress and inflammation in CD4 + T cells with PPAR-γ signaling involvement. This study highlights the pivotal role of BTK in autoreactive CD4+ T cells and provides a theoretical foundation for the therapeutic application of the small-molecule BTK inhibitors in AU. BTK was initially discovered for its role in X-linked agammaglobulinemia [41]. Patients with BTK gene mutations fail to produce antibodies due to defective B cell development, leading to severe humoral immunodeficiency. Subsequent studies revealed the importance of BTK in myeloid cells, including monocytes, macrophages, neutrophils, and neuroimmune cells like microglia [2–4]. For a long time, BTK was thought to be absent in T cells due to its low transcriptional levels [42]. However, during the treatment of chronic lymphocytic leukemia (CLL) patients with BTK inhibitors, researchers observed a reduction in total T cell numbers, their activation/exhaustion markers and Th17 subset frequency [43, 44]. Additionally, combining BTK inhibitors with CAR-T cell therapy reduced the risk of cytokine release syndrome [45]. These findings suggested a potential role of BTK in T cells. Similarly, studies on autoimmune encephalomyelitis showed that BTK inhibitors effectively reduced effector T cell proportions and cytokine secretion, although these therapeutic effects have been conventionally interpreted as secondary to B cells or myeloid cells modulation rather than direct T cell-intrinsic regulation [16, 46]. It was not until 2020 that Xu et al. demonstrated that BTK, despite low mRNA levels, is expressed at protein levels comparable to those in B cells and mediates T cell activation through the TCR/PLC-γ pathway, promoting autoimmune aplastic anemia [5]. Nevertheless, the understanding of BTK in T cells remains limited, necessitating further investigation into its role in autoreactive T cells. AU is a primarily CD4+ T cell-mediated inflammatory disease [9], of which pathogenesis is not fully understood. In this study, we observed significant upregulation of BTK expression and activation in CD4+ T cells from patients with AU and EAU mice, suggesting that BTK may critically regulate CD4+ T cell responses in AU pathogenesis. Prior studies have demonstrated elevated BTK expression and phosphorylation in effector/memory T cells, with BTK mediating CD4+ T cell activation in aplastic anemia [5]. Consistent with these findings, our results also established that BTK signaling is essential for CD4+ T cell activation and effector differentiation in EAU mice. Notably, we extended these observations by systematically comparing BTK activity across functionally distinct CD4+ T cell subsets including Th17 and Treg. Our data revealed a striking preferential enhancement of BTK expression and activation in pro-inflammatory Th17 cells compared to Treg cells. These results implicated BTK as a pivotal regulator of AU pathogenesis, particularly within pro-inflammatory CD4+ T cell populations, and provided a mechanistic rationale for targeting BTK in therapeutic interventions in our following experiments. BTKi were initially developed for B cell-related lymphomas. The success of ibrutinib and acalabrutinib revolutionized the treatment of CLL [47]. Subsequently, as understanding of BTK biology advanced, the potential of BTKi in autoimmune diseases began to emerge [4, 5, 15, 16, 20–22]. Our study demonstrated that BTKi alleviated ocular and systemic inflammation in EAU mice without affecting body weight or liver/kidney pathology (Fig.S1). Interestingly, its immunoregulatory effects rely on the suppression of the polarization of pathological CD4 + T cell subsets and inflammatory cytokine secretion in IRBP-specific CD4 + T cells, while having no significant impact on Treg. This selectivity likely reflects differential dependence on BTK signaling during subset polarization. Although we observed elevated BTK phosphorylation in Treg-polarizing CD4 + T cells compared to undifferentiated Th0 cells, Treg differentiation itself was found to be BTK-independent. In contrast, Th17 cells, which exhibited much higher BTK expression and activation than Tregs, demonstrated marked reliance on BTK signaling. BTK inhibition significantly impaired Th17 polarization and abolished the pathogenic capacity of IRBP-specific CD4+ T cells, as shown by reduced the secretion of Th17-related cytokine like IL-17A/GMCSF and attenuated disease induction in vivo. These findings collectively establish BTK as a non-redundant regulator of Th17 differentiation and pathogenicity. Moreover, its immunoregulatory effects were also validated in CD4+ T cells from AU patients, suggesting that BTK inhibitors hold promise as a novel therapeutic agent for AU. PPAR-γ, a member of PPARs family, is widely expressed in immune cells and involved in immune tolerance [38]. Downregulated PPAR-γ was observed in many autoimmune diseases including psoriasis [37] and multiple sclerosis [38]. Studies also have shown that PPAR-γ inhibits the expression of inflammatory cytokines [38, 48] and differentiation towards Th1 and Th17 in CD4+ T cells [37, 49, 50]. Additionally, PPAR-γ’s effects on ROS reduction and oxidative stress mitigation also contribute to its anti-inflammatory role. Numerous studies have linked oxidative stress to the pathogenesis of autoimmune diseases, including AU [51–56], where it forms a vicious cycle with immune inflammation. ROS strongly activates inflammatory pathways such as NF-κB and STAT, promoting the transcription of cytokines and driving T cell polarization toward Th17 [55, 57], while subsequent immune activation further exacerbates oxidative stress. PPAR-γ mitigates oxidative stress by inhibiting NADPH oxidase to reduce ROS generation [58] and upregulating antioxidant proteins [59], avoiding inflammation caused by redox imbalance. Our study found that BTK inhibition reduced ROS levels and NF-κB activation, while upregulated the PPAR-γ in CD4+ T cells. And the PPAR-γ inhibition prevented BTKi’s immunoregulatory effects. These indicated that PPAR-γ is involved in the immunomodulatory effect of BTK inhibition, although the direct relationship between BTK and PPAR-γ has not been revealed currently. According to the previous studies, extracellular signal-regulated kinase 1/2 (ERK1/2), an important molecule downstream of BTK signaling [60–63], can induce the phosphorylation of PPAR-γ directly, leading to its functional downregulation and degradation [64–66]. Thus, the downregulation of ERK1/2 signaling induced by BTK inhibition could provide a plausible explanation for the PPAR-γ upregulation observed after BTK inhibition in our study. However, there are also several limitations in our study. In addition to CD4+ T cells and B cells, other immune cells including neutrophils and microglia also contribute to autoimmune uveitis directly or indirectly [67–70]. Although we have demonstrated that the immunoregulatory effect of BTK inhibition on CD4+ T cells occurs independently of B cells, existing literature indicates that BTK also contributes to autoimmune pathogenesis by modulating macrophages and neutrophils [4, 5, 15, 16]. We therefore hypothesize that BTK inhibition may alleviate uveitis via these additional cellular pathways, a possibility that warrants systematic future validation. Furthermore, while our study implicates the involvement of PPAR-γ in the immunoregulatory effects of BTK inhibition, the precise underlying mechanisms require further elucidation. Conclusion In summary, this study innovatively demonstrates the critical role of BTK in the pathogenic CD4+ T cells from AU, and establishes that BTK inhibition alleviates AU by ameliorating oxidative stress and immune inflammation in CD4+ T cells with PPAR-γ signaling involvement, and suppressing Th1 and Th17 polarization. These findings not only deepen our understanding of the immune-inflammatory mechanisms of CD4+ T cells in AU, but also provide a novel therapeutic target for AU treatment. Furthermore, this study lays a solid theoretical foundation for the clinical application of small-molecule BTKi in AU, paving the way for the development of more precise immunomodulatory therapies. Supplementary Information Supplementary Material 1. Fig. S1 Safety Profile of BTKi at Therapeutic Doses in EAU Mice.(A) Body weight changes in EAU mice treated with BTKi or vehicle. Data are presented as mean ± SD. n=5. Statistical analysis was performed using t-tests.(B) Representative histopathological images of liver and kidney tissue from treated EAU mice (H&E staining). No significant pathological alterations were observed in BTKi-treated animals compared to controls. Supplementary Material 1. Fig. S1 Safety Profile of BTKi at Therapeutic Doses in EAU Mice.(A) Body weight changes in EAU mice treated with BTKi or vehicle. Data are presented as mean ± SD. n=5. Statistical analysis was performed using t-tests.(B) Representative histopathological images of liver and kidney tissue from treated EAU mice (H&E staining). No significant pathological alterations were observed in BTKi-treated animals compared to controls. Supplementary Material 2. Fig.S2 BTKi Administration from Day 8 Alleviates Ocular and Systemic CD4+ T cell Inflammation in EAU Mice (A) Experimental timeline: EAU was induced in C57BL/6 mice on Day 0. On Day 7, fundus imaging was performed to screen mice with early signs of EAU, which were then randomly assigned to either the BTKi treatment group or the vehicle control group. From Day 8 to Day 13, mice received either BTKi (3 mg/kg/day) or vehicle via oral gavage. Fundus imaging was repeated and tissue were collected on Day 14. (B) Representative fundus images taken on Day 7 post-immunization showing mild optic disc edema (white arrow) in EAU mice compared to blank controls without IRBP immunization. (C) Representative fundus photographs, fluorescein angiography images, and retinal H&E staining sections from vehicle- and BTKi-treated EAU mice on Day 14. Vehicle- treated EAU mice exhibited severe retinal edema, vascular leakage, retinal folding, and inflammatory cell infiltration. In contrast, BTKi-treated EAU mice showed reduced retinal edema, leakage, folding, and inflammatory infiltration. (D) Bar graphs summarizing clinical scores and pathological scores for vehicle-treated and BTKi-treated EAU mice. (E-F) Representative flow cytometry plots and corresponding bar graphs show the frequencies of Th17, Th1, and GMCSF+ CD4+ T cells in draining lymph nodes and spleens. BTKi-treated EAU mice showed significantly reduced proportions of these cell subsets compared to vehicle-treated EAU mice. Data are presented as mean ± SD. Statistical analysis was performed using ANOVA and t-tests. n=8 *p<0.05,**p<0.01,***p<0.005,****p<0.001,nsp≥0.05. Supplementary Material 2. Fig.S2 BTKi Administration from Day 8 Alleviates Ocular and Systemic CD4+ T cell Inflammation in EAU Mice (A) Experimental timeline: EAU was induced in C57BL/6 mice on Day 0. On Day 7, fundus imaging was performed to screen mice with early signs of EAU, which were then randomly assigned to either the BTKi treatment group or the vehicle control group. From Day 8 to Day 13, mice received either BTKi (3 mg/kg/day) or vehicle via oral gavage. Fundus imaging was repeated and tissue were collected on Day 14. (B) Representative fundus images taken on Day 7 post-immunization showing mild optic disc edema (white arrow) in EAU mice compared to blank controls without IRBP immunization. (C) Representative fundus photographs, fluorescein angiography images, and retinal H&E staining sections from vehicle- and BTKi-treated EAU mice on Day 14. Vehicle- treated EAU mice exhibited severe retinal edema, vascular leakage, retinal folding, and inflammatory cell infiltration. In contrast, BTKi-treated EAU mice showed reduced retinal edema, leakage, folding, and inflammatory infiltration. (D) Bar graphs summarizing clinical scores and pathological scores for vehicle-treated and BTKi-treated EAU mice. (E-F) Representative flow cytometry plots and corresponding bar graphs show the frequencies of Th17, Th1, and GMCSF+ CD4+ T cells in draining lymph nodes and spleens. BTKi-treated EAU mice showed significantly reduced proportions of these cell subsets compared to vehicle-treated EAU mice. Data are presented as mean ± SD. Statistical analysis was performed using ANOVA and t-tests. n=8 *p<0.05,**p<0.01,***p<0.005,****p<0.001,nsp≥0.05. Supplementary Material 3. Fig.S3 BTK inhibition alleviates EAU independent of B cells (A) Experimental timeline: Mice were administered an anti-CD20 antibody via tail vein injection three days prior to EAU induction to deplete B cells. On Day -1, blood was collected from the tail vein, and flow cytometry was performed to assess B cell depletion. Only mice with confirmed B cell depletion were used for EAU induction. From Day 3 onward, mice received either BTKi (3 mg/kg/day) or vehicle via oral gavage. Fundus imaging and tissue collection were performed on day 14 post-immunization. (B) Representative flow cytometry plots showing the proportion of B cells in tail vein blood on Day -1 from mice treated with either anti-CD20 antibody or an isotype control antibody. (C) Representative flow cytometry plots displaying the proportion of B cells in lymph nodes on Day 14 from mice treated with either anti-CD20 antibody or an isotype control antibody. (D) Representative fundus photographs, fluorescein angiography images, and retinal H&E staining sections from B cell-depleted EAU mice treated with either vehicle or BTKi, taken on Day 14. Vehicle-treated EAU mice exhibited severe retinal edema, vascular leakage, retinal folding, and inflammatory cell infiltration. In contrast, BTKi-treated EAU mice showed marked reduction in these pathological features. (E) Bar graphs summarizing clinical and pathological scores for B cell-depleted EAU mice treated with vehicle or BTKi. (F-G) Representative flow cytometry plots and corresponding bar graphs showing the frequencies of Th17, Th1, and GMCSF+ CD4+ T cells in draining lymph nodes and spleens. BTKi-treated EAU mice exhibited significantly reduced proportions of these cell subsets compared to vehicle-treated EAU mice following B cell depletion. Data are presented as mean ± SD. Statistical analysis was performed using ANOVA and t-tests. n=7 *p<0.05,**p<0.01,***p<0.005,****p<0.001,nsp≥0.05. Supplementary Material 3. Fig.S3 BTK inhibition alleviates EAU independent of B cells (A) Experimental timeline: Mice were administered an anti-CD20 antibody via tail vein injection three days prior to EAU induction to deplete B cells. On Day -1, blood was collected from the tail vein, and flow cytometry was performed to assess B cell depletion. Only mice with confirmed B cell depletion were used for EAU induction. From Day 3 onward, mice received either BTKi (3 mg/kg/day) or vehicle via oral gavage. Fundus imaging and tissue collection were performed on day 14 post-immunization. (B) Representative flow cytometry plots showing the proportion of B cells in tail vein blood on Day -1 from mice treated with either anti-CD20 antibody or an isotype control antibody. (C) Representative flow cytometry plots displaying the proportion of B cells in lymph nodes on Day 14 from mice treated with either anti-CD20 antibody or an isotype control antibody. (D) Representative fundus photographs, fluorescein angiography images, and retinal H&E staining sections from B cell-depleted EAU mice treated with either vehicle or BTKi, taken on Day 14. Vehicle-treated EAU mice exhibited severe retinal edema, vascular leakage, retinal folding, and inflammatory cell infiltration. In contrast, BTKi-treated EAU mice showed marked reduction in these pathological features. (E) Bar graphs summarizing clinical and pathological scores for B cell-depleted EAU mice treated with vehicle or BTKi. (F-G) Representative flow cytometry plots and corresponding bar graphs showing the frequencies of Th17, Th1, and GMCSF+ CD4+ T cells in draining lymph nodes and spleens. BTKi-treated EAU mice exhibited significantly reduced proportions of these cell subsets compared to vehicle-treated EAU mice following B cell depletion. Data are presented as mean ± SD. Statistical analysis was performed using ANOVA and t-tests. n=7 *p<0.05,**p<0.01,***p<0.005,****p<0.001,nsp≥0.05. Supplementary Material 4. Fig. S4 BTKi Exhibits No Cytotoxicity and No Induction of Apoptosis of CD4+T Cells in vitro (A-B) Heatmap and bar chart showing viability of lymph node cells treated with increasing concentrations of BTKi (0–10 μM, 72 h). No significant toxicity was observed at therapeutic doses. (C-E) Representative flow cytometry plots and bar graphs show that BTKi does not significantly affect early apoptosis (PI- Annexin V+) and late apoptosis (PI+ Annexin V+) rates of CD4+ T cells. Data are presented as mean ± SD. Statistical analysis was performed using ANOVA and t-tests. n=4-6*p<0.05,**p<0.01,***p<0.005,****p<0.001,nsp≥0.05. Supplementary Material 4. Fig. S4 BTKi Exhibits No Cytotoxicity and No Induction of Apoptosis of CD4+T Cells in vitro (A-B) Heatmap and bar chart showing viability of lymph node cells treated with increasing concentrations of BTKi (0–10 μM, 72 h). No significant toxicity was observed at therapeutic doses. (C-E) Representative flow cytometry plots and bar graphs show that BTKi does not significantly affect early apoptosis (PI- Annexin V+) and late apoptosis (PI+ Annexin V+) rates of CD4+ T cells. Data are presented as mean ± SD. Statistical analysis was performed using ANOVA and t-tests. n=4-6*p<0.05,**p<0.01,***p<0.005,****p<0.001,nsp≥0.05. Supplementary Material 5. Fig. S5 BTK Inhibition Alters the Transcriptome of CD4+ T Cells. (A) PCA of CD4+ T cells stimulated with IRBP in the presence or absence of BTKi. BTKi treatment induced distinct transcriptional clustering. (B) Volcano plot of DEGs in BTKi-treated versus vehicle-treated CD4+ T cells. (C-D) GO enrichment analysis of DEGs after BTK inhibition. Supplementary Material 5. Fig. S5 BTK Inhibition Alters the Transcriptome of CD4+ T Cells. (A) PCA of CD4+ T cells stimulated with IRBP in the presence or absence of BTKi. BTKi treatment induced distinct transcriptional clustering. (B) Volcano plot of DEGs in BTKi-treated versus vehicle-treated CD4+ T cells. (C-D) GO enrichment analysis of DEGs after BTK inhibition. Supplementary Material 6. Fig. S6 BTK Inhibition Downregulates Ocular ROS in vivo and TNF-α of CD4+T cells in vitro. (A) Representative flow cytometry histograms and bar graphs show significantly reduced levels of reactive oxygen species (ROS) in the retinal tissue of EAU mice with BTKi treatment. (B) Representative flow cytometry plots and bar graphs display the expression of TNF-α in CD4+ T cells under IRBP stimulation in vitro, cultured with various concentrations of BTKi. Statistical analysis was performed using ANOVA and t-tests. n= 6-8 *p<0.05,**p<0.01,***p<0.005,****p<0.001,nsp≥0.05. Supplementary Material 6. Fig. S6 BTK Inhibition Downregulates Ocular ROS in vivo and TNF-α of CD4+T cells in vitro. (A) Representative flow cytometry histograms and bar graphs show significantly reduced levels of reactive oxygen species (ROS) in the retinal tissue of EAU mice with BTKi treatment. (B) Representative flow cytometry plots and bar graphs display the expression of TNF-α in CD4+ T cells under IRBP stimulation in vitro, cultured with various concentrations of BTKi. Statistical analysis was performed using ANOVA and t-tests. n= 6-8 *p<0.05,**p<0.01,***p<0.005,****p<0.001,nsp≥0.05. Supplementary Material 7. Fig. S7 The Th0 Polarization Control and Gating Strategies for Fow Cytometry Analysis. (A-C) Th0 condition used as a control for the Th1(A), Th17(B), Treg(C) polarization assays. (D) Gating strategy for Th1, Th17 and GMCSF+CD4+T cells. (E) Gating strategy for Treg. (F) Gating strategy for immunocytes in retina tissue. Supplementary Material 7. Fig. S7 The Th0 Polarization Control and Gating Strategies for Fow Cytometry Analysis. (A-C) Th0 condition used as a control for the Th1(A), Th17(B), Treg(C) polarization assays. (D) Gating strategy for Th1, Th17 and GMCSF+CD4+T cells. (E) Gating strategy for Treg. (F) Gating strategy for immunocytes in retina tissue. Supplementary Material 8. Supplementary Material 8. Supplementary Material 9. Supplementary Material 9. Supplementary Material 10. Supplementary Material 10.